New cancer drug karonudib tested for first time in humans

NCT ID NCT03036228

Completed Disease control Sponsor: Thomas Helleday Foundation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Karonudib (TH1579)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors.
What could go wrong: This is a very early Phase 1 trial with only 63 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early cancer drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cervical carcinoma endometrial carcinoma fallopian tube cancer fallopian tube serous adenocarcinoma hormone-resistant prostate carcinoma neoplasm ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Karolinska University Hospital

Stockholm, Sweden
Sahlgrenska University Hospital

Gothenburg, Sweden
Uppsala University Hospital

Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.